Idorsia is a high-potential biopharmaceutical company, with an experienced team of over 1,200 highly qualified professionals, a full R&D pipeline, state-of-the-art facilities, and a strong balance sheet – the ideal constellation for bringing successful medicines to the market.
We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.
Idorsia is specialized in the discovery and development of small molecules, with the aim of transforming the horizon of therapeutic options. We have a broad, diversified and balanced development pipeline, covering multiple therapeutic areas.
Hegenheimermattweg 91, 4123 Allschwil – Switzerland
|Date||Trading entity / Person||Association||Trade type||Volume|
|11.05.22||None||Non-Executive member||Buy||CHF 98,179.90|
|10.05.22||None||Non-Executive member||Buy||CHF 109,660.30|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.